Medscape News - GAP: IVIG Negative in Alzheimer's, But Some Hints of Benefit - Susan Jeffrey

 – July 17, 2013  –– 

Final results of a pivotal phase 3 trial confirm that overall, there was no significant effect of treatment with intravenous immunoglobulin (IVIG; Gammagard, Baxter International Inc) on the co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease (AD). Mary Sano, PhD, Professor of Psychiatry, Director of The Alzheimer's Disease Research Center at the Icahn School of Medicine at Mount Sinai, and also a member of the executive committee for the trial, said these results, despite being negative, make a significant contribution.
-Dr. Mary Sano, Associate Dean for Clinical Research, Professor, Psychiatry, Icahn School of Medicine at Mount Sinai
Learn more